Semaglutide is now well known as the active ingredient in Novo Nordisks blockbuster type 2 diabetes drug Ozempic and weight-loss drug Wegovy, which were approved by the US Food and Drug Administration in 2017 and 2021, respectively
FDA Approval and Intended Use Ozempic received FDA approval in 2017 for treating type 2 diabetes
Each batch is tested to meet specific standards before release
Theres a big difference between mentioning a problem and warning of a problem
Although the drug has a long-standing history of use to treat Type 2 diabetes and its symptoms, semaglutide is now being used to address weight loss in non-diabetic patients and showing dramatic effects
Additionally, semaglutide suppresses glucagon release , a hormone that raises blood sugar, thereby helping to maintain more stable glucose levels throughout the day